264 related articles for article (PubMed ID: 25226113)
1. Amyloid imaging in Alzheimer's disease: a literature review.
Saidlitz P; Voisin T; Vellas B; Payoux P; Gabelle A; Formaglio M; Delrieu J
J Nutr Health Aging; 2014 Jul; 18(7):723-40. PubMed ID: 25226113
[TBL] [Abstract][Full Text] [Related]
2. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
[TBL] [Abstract][Full Text] [Related]
3. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
[TBL] [Abstract][Full Text] [Related]
4. Current status of PET-imaging probes of β-amyloid plaques.
Koo J; Byun Y
Arch Pharm Res; 2013 Oct; 36(10):1178-84. PubMed ID: 23812777
[TBL] [Abstract][Full Text] [Related]
5. Florbetapir F 18 for brain imaging of β-amyloid plaques.
Romano M; Buratti E
Drugs Today (Barc); 2013 Mar; 49(3):181-93. PubMed ID: 23527322
[TBL] [Abstract][Full Text] [Related]
6. Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.
Okamura N; Yanai K
IDrugs; 2010 Dec; 13(12):890-9. PubMed ID: 21154149
[TBL] [Abstract][Full Text] [Related]
7. Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid.
Beach TG; Schneider JA; Sue LI; Serrano G; Dugger BN; Monsell SE; Kukull W
J Neuropathol Exp Neurol; 2014 Oct; 73(10):948-53. PubMed ID: 25192053
[TBL] [Abstract][Full Text] [Related]
8. Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue.
Choi SR; Schneider JA; Bennett DA; Beach TG; Bedell BJ; Zehntner SP; Krautkramer MJ; Kung HF; Skovronsky DM; Hefti F; Clark CM
Alzheimer Dis Assoc Disord; 2012; 26(1):8-16. PubMed ID: 22354138
[TBL] [Abstract][Full Text] [Related]
9. Estimation of amyloid distribution by [
Thal DR; Beach TG; Zanette M; Lilja J; Heurling K; Chakrabarty A; Ismail A; Farrar G; Buckley C; Smith APL
Acta Neuropathol; 2018 Oct; 136(4):557-567. PubMed ID: 30123935
[TBL] [Abstract][Full Text] [Related]
10. Florbetapir (18F) for brain amyloid positron emission tomography: highlights on the European marketing approval.
Cortes-Blanco A; Prieto-Yerro C; Martinez-Lazaro R; Zamora J; Jiménez-Huete A; Haberkamp M; Pohly J; Enzmann H; Zinserling J; Strassmann V; Broich K
Alzheimers Dement; 2014 Oct; 10(5 Suppl):S395-9. PubMed ID: 24418060
[TBL] [Abstract][Full Text] [Related]
11. Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.
Hornberger J; Bae J; Watson I; Johnston J; Happich M
Curr Med Res Opin; 2017 Apr; 33(4):675-685. PubMed ID: 28035842
[TBL] [Abstract][Full Text] [Related]
12. Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection.
Ikonomovic MD; Buckley CJ; Heurling K; Sherwin P; Jones PA; Zanette M; Mathis CA; Klunk WE; Chakrabarty A; Ironside J; Ismail A; Smith C; Thal DR; Beach TG; Farrar G; Smith AP
Acta Neuropathol Commun; 2016 Dec; 4(1):130. PubMed ID: 27955679
[TBL] [Abstract][Full Text] [Related]
13. Infrequent false positive [
Ikonomovic MD; Fantoni ER; Farrar G; Salloway S
Alzheimers Res Ther; 2018 Jun; 10(1):60. PubMed ID: 29935545
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
15. Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography.
Wolk DA; Zhang Z; Boudhar S; Clark CM; Pontecorvo MJ; Arnold SE
J Neurol Neurosurg Psychiatry; 2012 Sep; 83(9):923-6. PubMed ID: 22791901
[TBL] [Abstract][Full Text] [Related]
16. PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.
Siderowf A; Pontecorvo MJ; Shill HA; Mintun MA; Arora A; Joshi AD; Lu M; Adler CH; Galasko D; Liebsack C; Skovronsky DM; Sabbagh MN
BMC Neurol; 2014 Apr; 14():79. PubMed ID: 24716655
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
Morris E; Chalkidou A; Hammers A; Peacock J; Summers J; Keevil S
Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):374-385. PubMed ID: 26613792
[TBL] [Abstract][Full Text] [Related]
18. Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology.
Beach TG; Thal DR; Zanette M; Smith A; Buckley C
J Alzheimers Dis; 2016 Mar; 52(3):863-73. PubMed ID: 27031469
[TBL] [Abstract][Full Text] [Related]
19. Amyloid plaque imaging from IMPY/SPECT to AV-45/PET.
Kung MP; Weng CC; Lin KJ; Hsiao IT; Yen TC; Wey SP
Chang Gung Med J; 2012; 35(3):211-8. PubMed ID: 22735052
[TBL] [Abstract][Full Text] [Related]
20. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
de Lartigue J
Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
